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Abstract Long-term exposure to organic nitrates
influences different sections of the vascular bed hetero-
geneously. Continuous dosage of nitrates leads to the
development of tolerance both to the vascular effects and
to the unwanted adverse effect, headache. Human data on
the development of tolerance in different cranial arteries
over more than 24 h are lacking. We compared the vas-
cular changes of the middle cerebral, superficial temporal
and radial arteries during oral administration of isosor-
bide-5-mononitrate (5-ISMN) 30 mg three times daily for
7 days in 11 healthy subjects in a double-blind, random-
ised, placebo controlled cross-over design. Blood velocity
in the middle cerebral artery was measured with trans-
cranial Doppler and the diameters of the temporal and
radial arteries were measured with high frequency ultra-
sound. Headache recordings were compared to the
observed vascular changes over time. Tolerance was
complete within 24 h in the middle cerebral artery whilst
in the superficial temporal and the radial arteries, toler-
ance was only partial and developed much more slowly,
i.e. after 7 days correlating with the disappearance of NO-
induced headache. The present study thus demonstrated
the important differences in the time profiles of appear-
ance of nitrate tolerance in arteries of different vascular
beds in man. If vasodilatation is the cause of NO-induced
headache the results point to extracerebral arteries as the
locus of nociception. Due to a variety of other possible
pain-inducing effects of nitric oxide our results do not
exclude cerebral arteries.
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Introduction
Glyceryl trinitrate (GTN) (nitroglycerin) and isosorbide-
5-mononitrate (5-ISMN) have similar mechanisms of
actions and exert their effects through their active
metabolite nitric oxide (NO) [1] which is a potent reg-
ulator of vascular tone [2]. Both drugs possess a well-
known ability to provoke a vascular type headache in
healthy subjects [3, 4]. In sufferers of migraine GTN
induces migraine attacks which are clinically identical to
spontaneous attacks, indicating that drug-induced as well
as spontaneous attacks may be caused by NO [5].
Headache is the most prominent adverse effect of nitrate
therapy in sufferers of cardiovascular diseases [6].
However, during long-term nitrate treatment, headache
often abates over a period of time, whilst the anti-anginal
effect remains, implying tolerance in cephalic more than
in coronary arteries. Human data on the development of
nitrate tolerance in different cranial arteries are currently
lacking. A correlation between the vascular adaptation
and tolerance to headache could lead to insight into
vascular headache mechanisms in general. We therefore
investigated the development of nitrate tolerance in the
middle cerebral, superficial temporal, and radial arter-
ies during oral administration of controlled release
formulation of 5-ISMN (30 mg 9 3) for 7 days and
compared the results to the headache response previously
published [7].
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Methods
Material, design and measurements
A total of 16 healthy subjects, 15 females and 1 male, aged
30–51 years (mean 38.7 years) participated in the study.
Subjects with a history of migraine and subjects with
other headaches more than 1 day/month, subjects on daily
medication other than contraceptives, and pregnant and
nursing women were excluded. Prior to inclusion in the
study all subjects had experienced headache, but no
hypotension after a test dose of 0.5 mg glyceryl trinitrate
administered sublingually. An interval of at least 3 days
separated the study period from the day of test dose given.
Weak analgesics (paracetamol, acetylsalicylic acid), anti-
emetic (metoclopramide), tea, coffee, alcohol or tobacco
were not allowed from 8 h prior to the haemodynamic
measurements, neither were vasoactive migraine drugs
(triptans) 24 h before the measurements. The study fol-
lowed the Helsinki II declaration and was approved by the
National Board of Health and also by the Ethics Committee
of the County of Copenhagen. All subjects gave their
written informed consent and were free to withdraw at any
time and to receive treatment if needed.
The study followed a double blind, randomised, placebo
controlled cross-over design. 5-ISMN 30 mg in a controlled
release formulation (Imdur AstraZeneca) or placebo was
administered orally three times a day during two separate
periods of 7 days, each period being separated from the
other by at least a fortnight of wash-out. The time-averaged
mean of the maximal blood velocities (Vmean) in both
middle cerebral arteries (MCA) was measured with trans-
cranial Doppler (Transscan, EME) [8]. The fixpoint
measurement of Vmean was a point along the MCA, which
was free of the bifurcation between the MCA and the
anterior cerebral artery, but as close to it as possible [9].
This fixpoint was then used throughout the study in each
individual, and every measurement was done after carefully
optimising the signal from this point. The diameters of the
left radial artery and both temporal arteries were measured
with a high resolution ultrasound scanning (Dermascan C,
Cortex Technology) [10]. A mean of four measurements
performed within 30 s was used to augment precision. An
individual fixpoint of each subject along the right frontal
branch of the superficial temporal artery and along the
radial artery of the left wrist was used throughout the study.
Day to day positions of measurements were reproduced by
recording the scanning position in relation to the angle and
distance relative to the orbito-meatal line (temporal artery)
and to the distal volar crest of the wrist (radial artery) [10,
11]. Blood pressure and heart rate were measured with an
automatic inflatable arm cuff (Tonoprint).
Procedure
The subjects arrived in the laboratory at 09.00 hours. After
30 min of rest in the supine position, baseline values of
Vmean of MCA, diameters of the temporal and radial
arteries, blood pressure and heart rate were recorded, fol-
lowed by an oral administration of 30 mg 5-ISMN or
placebo. The subjects were then allowed to leave the lab-
oratory, but instructed to return 4 h later for a repetition of
the haemodynamic measurements, preceded by 30 min of
supine rest. Afterwards the subjects were discharged from
hospital and asked to return to the laboratory for repeated
measurements the next day, and after 3 and 7 days at
11.00 hours (i.e. at time of peak plasma concentration, 4 h
post morning dose at 07.00 hours [4]). Headache severity
was scored on a numerical verbal rating scale from 0 to 10
(1 representing a prepain, including a feeling of pressure
and pulsation, 5 a moderate headache, and 10 the worst
possible headache [7]. This was scored in a headache diary
every day at 07.00, 15.00, 18.00, and 22.00 hours. Each
subject was offered paracetamol/acetyl-salicylic acid
for immediate or later use, if headache became intolerable.
5-ISMN or placebo was administered for 7 days by
the subjects themselves at home at 07.00, 15.00 and
22.00 hours. At each visit, compliance was tested by cap-
sule count.
Statistical analysis
The arterial responses were calculated in per cent of
baseline and expressed as mean and standard error of the
mean (±SEM), unless otherwise specified. Side-to-side
differences between the right and left middle cerebral
artery/temporal artery were analysed, using a t test for
paired data. Overall differences between periods (5-ISMN/
placebo) were evaluated by multivariate (three-way) anal-
ysis of variance at 0, 4, 24, 72 and 168 h. Changes over
time were analysed separately and significant changes
located by a multi-comparison procedure (range test, con-
fidence level 95%) [12] Statgrafics 3.0 was used throughout
for statistical analysis. For all analyses, a p value \0.05
was considered statistically significant.
Results
Five of 16 subjects withdrew within 24 h from start of the
5-ISMN period because of adverse effects [unacceptable
headache (1 subject), symptoms compatible with hypo-
tension (vertigo) (3 subjects), nausea (1 subject)]. Data
from these subjects were excluded from the statistical
analysis.
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Haemodynamic values at each investigative time point
are presented in Tables 1 and 2 (absolute values). To
facilitate a survey, and since no systematic side-to-side
differences were found (p [ 0.05), the results from the
right- and left-sided arteries are presented as mean values.
None of the pre-treatment values differed significantly
between the two study periods (p [ 0.05, t test for paired
data).
Changes in the middle cerebral artery
5-ISMN decreased Vmean compared to placebo (p = 0.02).
At 4 h after administration of 5-ISMN, Vmean had
decreased to 83 ± 3% of baseline (p \ 0.05). However,
after 24 h this effect was no longer present. No significant
changes over time were observed during placebo
(p = 0.25).
Changes in the temporal and radial arteries
5-ISMN dilated the arteries compared to placebo
(p = 0.0001, temporal artery; p = 0.0001, radial artery).
At 4 h post 5-ISMN administration the temporal artery was
dilated to 116 ± 3% of baseline (p \ 0.05). Maximal
dilatation to 124 ± 4% of baseline was measured 20 h
later (p \ 0.05). After 3 days, an attenuation of this effect
to 119 ± 5% of baseline was observed; however, this was
not significant (p [ 0.05, range test). After 7 days partial
tolerance of the temporal artery had developed (109 ± 3%
of baseline); thus, a significant attenuation of dilatory
effect was observed compared to peak value at 24 h
(p \ 0.05), but the artery was still significantly dilated
compared to baseline (p \ 0.05) (Fig. 1).
Four hours post 5-ISMN administration the radial artery
was dilated to 127 ± 5% of baseline (p \ 0.05). No further
change was observed at 24 and 72 h (p [ 0.05, range test).
After 7 days a significant attenuation compared to the
preceding values at 24 and 72 h (p \ 0.05) was observed
but the artery was still significantly dilated compared to
baseline (117 ± 4% of baseline) (p \ 0.05).
No significant changes over time were detected during
placebo (p = 0.38, temporal artery; p = 0.19, radial
artery).
Heart rate and blood pressure
5-ISMN did not change the responses compared to placebo
(p [ 0.05). Systolic and diastolic blood pressure showed
no changes at 4 and 24 h post 5-ISMN; however, systolic
and diastolic blood pressure increased after 3 days com-
pared to values at 4 and 24 h (p \ 0.05). This effect was
not present after 7 days (p [ 0.05). No significant changes
of blood pressure over time were observed during placebo
(p [ 0.7). No significant changes of heart rate over time
Table 1 Vmean of the middle cerebral artery (MCA) and diameters of the temporal (TA) and radial arteries (RA) during 5-ISMN and placebo
[mean (absolute values), SEM]
Time Vmean, MCA (cm/s, SEM) Diameter, TA (mm, SEM) Diameter, RA (mm, SEM)
Hours 5-ISMN Placebo 5-ISMN Placebo 5-ISMN Placebo
0 71 (4) 71 (4) 0.95 (0.04) 0.98 (0.04) 2.42 (0.09) 2.46 (0.09)
4 58 (3) 67 (4) 1.09 (0.04) 1.01 (0.04) 3.08 (0.17) 2.61 (0.13)
24 66 (4) 69 (4) 1.15 (0.03) 0.98 (0.03) 3.08 (0.12) 2.62 (0.11)
72 68 (3) 70 (3) 1.11 (0.05) 0.97 (0.03) 3.18 (0.15) 2.56 (0.09)
168 68 (3) 69 (3) 1.03 (0.04) 0.98 (0.04) 2.82 (0.13) 2.58 (0.11)
MCA middle cerebral artery, TA temporal artery, RA radial artery, Vmean mean blood velocity, SEM standard error of the mean
Table 2 Blood pressure and heart rate during 5-ISMN and placebo [mean (absolute values), SEM]
Time Systolic blood pressure (mmHg, SEM) Diastolic blood pressure (mmHg, SEM) Heart rate (Beats/min, SEM)
Hours 5-ISMN Placebo 5-ISMN Placebo 5-ISMN Placebo
0 111 (4) 108 (2) 70 (3) 74 (3) 66 (3) 65 (2)
4 108 (4) 109 (2) 68(4) 71 (4) 67 (1) 67 (2)
24 109 (5) 106 (4) 68 (4) 70 (4) 66 (3) 65 (2)
72 115 (3) 107 (4) 75 (3) 71 (5) 68 (2) 68 (2)
168 112 (4) 108 (4) 72 (4) 70 (3) 73 (3) 75 (2)
SEM standard error of the mean
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was observed during 5-ISMN (p = 0.23) while heart rate
increased significantly after 7 days compared to baseline
during placebo (p \ 0.05).
Discussion
This study shows that the development of tolerance to NO
is fast in the middle cerebral artery but slow in extracere-
bral arteries and that tolerance in headache similarly
develops slowly.
Nitrate tolerance is a complex phenomenon, which
involves neurohormonal counter-regulation, collectively
classified as pseudotolerance, a well as intrinsic vascular
processes, defined as vascular tolerance [13].
An isosorbide 5-mononitrate (5-ISMN) dose of 30 mg
was chosen because a previously performed dose-response
study showed that this dose induced significant changes in
the radial- and temporal arterial diameters and no major
drops in blood pressure or other severe adverse effects [4].
It is probably the maximum tolerable dose when given
thrice daily because 5 out of 16 subjects discontinued the
study early due to adverse events, see results. 5-ISMN t.i.d
was chosen as the NO donor because of its long half life of
4–5 h [14, 15]. In addition, a controlled release formulation
was used. Given thrice daily it results in a rather continu-
ous exposure to NO thus enhancing the development of
tolerance [16].
Regional cerebral blood flow (rCBF) was not measured
in the present study, but in single-dose studies with GTN
have shown either an unchanged rCBF in two SPECT
(single photon emission computed tomography) studies
[17, 18] and in one PET (positron emission tomography)
study [19] or a 23% increase in one PET study [20].
Although the Doppler technique does not allow direct
measurements of the diameter of the middle cerebral artery
(MCA), the relative diameter change can be estimated from
the relation: regional cerebral blood flow (rCBF) = mean
velocity 9 cross sectional area of the artery [21]. Whether
unchanged or slightly increased rCBF is present a decrease
in Vmean, as in the present study, will indicate a dilatation of
MCA. With an unchanged rCBF it can be estimated that 5-
ISMN caused a 10% increase in the diameter of the middle
cerebral artery (MCA). If the rCBF is increased the
increase of the diameter of the MCA would be more pro-
nounced. The decrease of Vmean of 17% is in the same
range as found previously in healthy subjects (20%) after
i.v. GTN 0.5 lg/(kg min) in a study where rCBF was
measured simultaneously with SPECT and was unchanged
[18]. This is somewhat less than the decrease of 28%
observed with half the dose of GTN in migraine patients
[22]. A comparable decrease (13%) in Vmean was found
in another study in healthy volunteers after i.v. GTN
0.5 lg/(kg min) [23].
In one study transdermal GTN (0.6 mg/h) for 7 days
was found to induce tolerance to GTN as measured by
forearm blood volume [24] whereas pentaerythritol tetra-
nitrate (60 mg three times a day) did not have this effect
[24]. The few existing clinical studies, using direct mea-
surements of diameter changes of the radial and temporal
arteries, have failed to demonstrate the appearance of
nitrate tolerance in these vessels within a study period of 7
[25] and 24–48 h of continuous GTN-infusion [26, 27].
The present study provides long-term data, up to a week,
on this phenomenon in the radial and superficial temporal
arteries for the first time. It is also the first clinical study of
nitrate tolerance in cerebral arteries, the time course of
which furthermore is compared to those of the temporal
and radial arteries. At 4 h after administration of the first
dose of 5-ISMN a significant dilatation was observed in
both cephalic and limb arteries. Complete tolerance
occurred already within 24 h of the first dose (a total of
four doses) in the middle cerebral artery. At 168 h (day
seven) partial tolerance was observed in the temporal and
radial arteries compared to peak values but the radial was
still dilated compared to baseline. The partial tolerance of
the temporal and radial arteries may, however, have
developed earlier than at 168 h as no measurements were
done in the interval between 72 and 168 h. Previous studies
[26–28], investigating the effects of nitrates on the tem-
poral and radial arteries, were not extended until the
development of tolerance, but support nevertheless the
present finding of a relatively late occurrence of tolerance
in these vessels. Thus, during 7 h of GTN-infusion in
healthy subjects the mean dilatation of the radial artery was
36% after 5 min of infusion of 0.5 lg/(kg min) and
remained stable over time [25]. In one study, GTN 0.5 lg/
(kg min) was infused for 24 h in healthy subjects;
































Fig. 1 The effect of 5-ISMN 30 mg t.i.d for 7 days on headache,
mean blood flow velocity in middle cerebral artery and diameter of
temporal artery. Headache was rated on a 0–10 scale. Median values
are given. Percentage changes are given for the arteries. A close
temporal association between the disappearance of headache and
attenuation of the dilatory potency of 5-ISMN in the temporal artery
was observed. The intracranial artery (middle cerebral artery) was
already tolerant within 24 h
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diameters of the radial and temporal arteries increased
significantly after 1 h of infusion followed by an attenua-
tion of this effect but tolerance was not observed [26]. In
another study, GTN GTN 0.5 lg/(kg min) was infused for
48 h in healthy subjects with no attenuation of the dilator
effect on the radial artery [27].
In vitro studies confirm a faster development of nitrate
tolerance in the intracranial arteries compared to peripheral
arteries [29, 30]. Thus, in smooth muscle cells cultured
from peripheral vessels, pre-treatment with GTN was
requested for 60 min in order to induce tolerance [29]. In
contrast, in smooth muscle cells from cerebral arteries a 5-
minute pre-treatment with GTN reduced the response to
rechallenge by [50% [30]. Also, time to recovery from
tolerance was shorter in cerebral artery smooth muscle
cells than in peripherally derived cells [30]. Collectively
these and other in vitro data [31–33] demonstrate that
vascular tolerance to NO-producing agents can be
accounted for by actions at the cell level [31–33]. Such
intrinsic abnormalities include decreased biotransformation
of organic nitrates to NO, desensitisation of the target
enzyme guanylyl cyclase, enhanced vascular superoxide
anion production, which degrades NO, and enhanced pro-
pensity for vasoconstriction due to increased endothelin
expression within the vascular smooth muscle [31–34].
Inhibition of mitochondrial aldehyde dehydrogenase
(ALDH-2) has in several studies been shown to be involved
in the development of tolerance to GTN [35–38] and GTN
tolerance was described as a syndrome characterized by
mitochondrial dysfunction [37]. Bioactivation of 5-ISMN,
however, presumably involves an ALDH-2-independent
pathway [36] and alternative explanations for the tolerance
to 5-ISMN should be investigated, see [13]. In the clinical
setting other mechanisms of tolerance than those at a cel-
lular level are considered to play a major role including a
neurohormonal counter regulation with response of the
sympathoadrenal axis and of the renin-angiotensin system
that counteracts the effects of the drug [13, 34]. For a
recent review on nitrate tolerance, see [13]. Cellular and
systemic mechanisms have most likely a differentiated
impact on arteries of different origin resulting in the dif-
ferent time-effect curves as observed in the present study.
A possible mechanism whereby NO could cause head-
ache is by dilatation of cerebral and extracerebral blood
vessels. This concept is supported by studies in which
arterial dilatation during and after infusion of GTN or oral
administration of 5-ISMN was consistently observed [4, 17,
18]. The present study demonstrated a significant dilatation
of both MCA, temporal and radial arteries at 4 h after
administration of the first dose of 5-ISMN. The 5-ISMN-
induced headache was most severe during the first couple of
days after 5-ISMN administration, followed by a gradual
attenuation, until a state of tolerance to headache had
developed on the 6th day [7]. A close temporal association
between the disappearance of headache and attenuation of
the 5-ISMN induced dilatation of the superficial temporal
artery was observed (Fig. 1). In contrast, tolerance in the
middle cerebral artery was complete and appeared already
after 24 h, i.e. earlier than the development of tolerance to
headache (Fig. 1). The fact that the temporal artery was still
dilated to a minor degree after 7 days, whereas headache had
disappeared indicates that there is most likely a threshold for
NO-induced headache. These findings suggest that the locus
of nociception in nitrate-induced headache could be related
to dilatation of extracerebral arteries including possibly the
middle meningeal artery, also a branch: of the external
carotid artery [39].
The present study of NO-induced headache does not
exclude the involvement of intracranial arteries in migraine
that may be caused by dilatation independent pain-inducing
effects of NO. Thus, migraine pain may possibly arise from
normally calibrated arteries due to sensitization of peri-
vascular sensory nerve terminals [40].
In conclusion, the development of nitrate tolerance is
faster and more complete in cerebral arteries than in small-
sized extracranial and middle-sized limb arteries. This may
reflect differentiated impact of cellular and systemic
mechanisms of tolerance in arteries of different size and
origin. If vasodilatation is the cause of NO-induced head-
ache, our results point to extracerebral arteries as the locus
of nociception.
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